Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ingenol disoxate - LEO Pharma

Drug Profile

Ingenol disoxate - LEO Pharma

Alternative Names: LEO-43204

Latest Information Update: 29 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma
  • Class Antiacnes; Antineoplastics; Carboxylic acids; Cyclopropanes; Esters; Isoxazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis; Squamous cell cancer
  • Phase II Acne vulgaris

Most Recent Events

  • 15 Jun 2018 LEO Pharma terminates a phase III trial in Squamous cell carcinoma (Prevention, Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in USA, Canada, France, Germany, Spain and United Kingdom (NCT03115476)
  • 01 Nov 2017 LEO Pharma completes a phase III trial for Actinic keratosis in United Kingdom and USA (Topical) (EudraCT2015-002449-71) (NCT02547233)
  • 10 Aug 2017 LEO Pharma completes a phase III trial in Actinic keratosis in USA and Germany (NCT02549339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top